Podcast appearances and mentions of Sheryl A Kingsberg

In the last 2 episodes we covered new updates in menopausal hormone therapy. However, we did not address TESTOSTERONE use. This episode idea comes from one our podcast family members and good friend, Eric. Eric is 100% correct: Testosterone replacement, when done correctly, has come along way. When is this indicated? Is this endorsed by professional medical/endocrine groups? What's the dose? We have fun stuff to review, so listen in!1. Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4660-4666. doi: 10.1210/jc.2019-01603. PMID: 31498871; PMCID: PMC6821450.2. Sharon J. Parish, James A. Simon, Susan R. Davis, Annamaria Giraldi, Irwin Goldstein, Sue W. Goldstein, Noel N. Kim, Sheryl A. Kingsberg, Abraham Morgentaler, Rossella E. Nappi, Kwangsung Park, Cynthia A. Stuenkel, Abdulmaged M. Traish, Linda Vignozzi, International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women, The Journal of Sexual Medicine, Volume 18, Issue 5, May 2021, Pages 849–867, https://doi.org/10.1016/j.jsxm.2020.10.0093. Levy, Barbara MD, MSCP; Simon, James A. MD, MSCP. A Contemporary View of Menopausal Hormone Therapy. Obstetrics & Gynecology 144(1):p 12-23, July 2024. | DOI: 10.1097/AOG.00000000000055534. NAMS The 2022 hormone therapy position statement of The North American Menopause Society: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf

Guest: Sheryl A. Kingsberg, PhD Guest: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF Guest: Risa Kagan, MD, FACOG, CCD, NCMP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG An average of 37.5 million menopausal women in the US between the ages of 45 and 64 experience symptoms such as hot flashes and joint pain, but there are other symptoms that we rarely talk about: symptoms like vaginal dryness and dyspareunia. Featuring a patient and a panel of experts, this discussion reviews strategies that can be used to help patients feel comfortable in bringing up their struggles with menopause along with how we can help relieve women from their pain. ©2019 NP-INR-US-00214 09/19

Guest: Sheryl A. Kingsberg, PhD Guest: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF Guest: Risa Kagan, MD, FACOG, CCD, NCMP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG An average of 37.5 million menopausal women in the US between the ages of 45 and 64 experience symptoms such as hot flashes and joint pain, but there are other symptoms that we rarely talk about: symptoms like vaginal dryness and dyspareunia. Featuring a patient and a panel of experts, this discussion reviews strategies that can be used to help patients feel comfortable in bringing up their struggles with menopause along with how we can help relieve women from their pain. ©2019 NP-INR-US-00214 09/19

Guest: Sheryl A. Kingsberg, PhD Guest: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF Guest: Risa Kagan, MD, FACOG, CCD, NCMP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG An average of 37.5 million menopausal women in the US between the ages of 45 and 64 experience symptoms such as hot flashes and joint pain, but there are other symptoms that we rarely talk about: symptoms like vaginal dryness and dyspareunia. Featuring a patient and a panel of experts, this discussion reviews strategies that can be used to help patients feel comfortable in bringing up their struggles with menopause along with how we can help relieve women from their pain. ©2019 NP-INR-US-00214 09/19

Guest: Sheryl A. Kingsberg, PhD Guest: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF Guest: Risa Kagan, MD, FACOG, CCD, NCMP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG An average of 37.5 million menopausal women in the US between the ages of 45 and 64 experience symptoms such as hot flashes and joint pain, but there are other symptoms that we rarely talk about: symptoms like vaginal dryness and dyspareunia. Featuring a patient and a panel of experts, this discussion reviews strategies that can be used to help patients feel comfortable in bringing up their struggles with menopause along with how we can help relieve women from their pain. ©2019 NP-INR-US-00214 09/19

Guest: Sheryl A. Kingsberg, PhD Guest: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF Guest: Risa Kagan, MD, FACOG, CCD, NCMP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG An average of 37.5 million menopausal women in the US between the ages of 45 and 64 experience symptoms such as hot flashes and joint pain, but there are other symptoms that we rarely talk about: symptoms like vaginal dryness and dyspareunia. Featuring a patient and a panel of experts, this discussion reviews strategies that can be used to help patients feel comfortable in bringing up their struggles with menopause along with how we can help relieve women from their pain. ©2019 NP-INR-US-00214 09/19

Guest: Sheryl A. Kingsberg, PhD Dr. Sheryl Kingsberg demonstrates counseling strategies clinicians can use with their patient when discussing dyspareunia in post-menopausal women. Dr. Sheryl Kingsberg is Chief of the Division of Behavioral Medicine in the Department of OB/GYN at University Hospitals Cleveland Medical Center and Professor of Reproductive Biology and Psychiatry at Case Western Reserve University School of Medicine in Cleveland, Ohio.

Host: Michael Krychman, MD Guest: Sheryl A. Kingsberg, PhD Flibanserin's approval by the FDA for women with hypoactive sexual desire disorder (HSDD), touted by the press as the "Pink Viagra," created an enormous amount of media hype across the nation. But the facts on this drug's mechanism of action, intended benefits, adverse effects, and efficacy borne in clinical trials have gone largely under the radar. Joining Dr. Michael Krychman to discuss the rise of flibanserin and its key takeaways for clinicians is Dr. Sheryl Kingsberg, Chief of the Division of Behavioral Medicine in the Department of OB/GYN and Professor in the Departments of Reproductive Biology and Psychiatry at Case Medical Center University Hospitals in Cleveland, Ohio.

Host: Michael Krychman, MD Guest: Sheryl A. Kingsberg, PhD Flibanserin's approval by the FDA for women with hypoactive sexual desire disorder (HSDD), touted by the press as the "Pink Viagra," created an enormous amount of media hype across the nation. But the facts on this drug's mechanism of action, intended benefits, adverse effects, and efficacy borne in clinical trials have gone largely under the radar. Joining Dr. Michael Krychman to discuss the rise of flibanserin and its key takeaways for clinicians is Dr. Sheryl Kingsberg, Chief of the Division of Behavioral Medicine in the Department of OB/GYN and Professor in the Departments of Reproductive Biology and Psychiatry at Case Medical Center University Hospitals in Cleveland, Ohio.

Host: Prathima Setty, MD Guest: Sheryl A. Kingsberg, PhD Hypoactive sexual desire disorder (HSDD) is the most prevalent sexual disorder for women of all ages, but it is also one of the most difficult to address. Clinicians need to understand the implications and address the concerns of their patients. Host Dr. Prathima Setty discusses this topic with Sheryl A. Kingsberg, PhD, Chief, Division of Behavioral Medicine, Department of Obstetrics/Gynecology, University Hospitals Case Medical Center, and Professor, Departments of Reproductive Biology and Psychiatry, Case Western Reserve University, Cleveland, OH. About NAMS The interview was conducted live at The North American Menopause Society (NAMS) 2014 meeting. Founded in 1989, NAMS is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field-including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education-makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit www.menopause.org.

Guest: Sheryl A. Kingsberg, PhD Host: Maureen Whelihan, MD Pain is one of the most significant barriers to pleasurable sex— and very common, affecting 15 to 25 percent of women at some point during their lifetime. Dyspareunia and vaginismus are two of the most common pain disorders. What are the signs and symptoms, and what are the questions you can ask your patients in order to assess whether they're having pain and what type? Dr. Sheryl Kingsberg, chief of the division of behavioral medicine in the department of OB/GYN at Case Medical Center University Hospitals in Cleveland, Ohio, joins host Dr. Maureen Whelihan to talk about treating dyspareunia and vaginismus through medication, behavioral therapy and pelvic floor physical therapy.